Bedinvetmab, sold under the brand name Librela, is a canine monoclonal antibody used for the control of pain associated with osteoarthritis in dogs.

[5][6] The most common side effects include increased blood urea nitrogen (an indicator of kidney function), urinary tract infection, bacterial skin infection, skin irritation (dermatitis), rash (erythema) or pain at injection site, vomiting (emesis), and weight loss (anorexia).

[5][6] Bedinvetmab is the first monoclonal antibody approved in the United States for controlling osteoarthritis pain in dogs.

[5] The weight of evidence from the two field studies demonstrated that bedinvetmab is effective at controlling pain associated with osteoarthritis in dogs when at least two doses are given 28 days apart.

[8] This article incorporates public domain material from the United States Department of Health and Human Services